Disclosures: Rui Li: Nothing to Disclose, Zhe Wang: Nothing to Disclose, Lixin Cheng: Nothing to Disclose, Zhiqiang Cheng: Nothing to Disclose, Qiong Wu: Nothing to Disclose, Qingxian Cai: Nothing to Disclose, Yijin Wang: Nothing to Disclose 1821 MAINTENANCE OF GOOD LIVER FUNCTION IS IMPORTANT FOR GOOD POST-PROGRESSION SURVIVAL WITH ATEZOLIZUMAB/BEVACIZUMAB IN ADVANCED HEPATOCELLULAR CARCINOMA Teiji Kuzuya 1 Naoto Kawabe 2 Yoshiki Hirooka 3 , 1 Fujita Health University Hospital: Fujita Ika Daigaku Byoin, 2 Fujita Health University, 3 Fujita Health University Hospital Background: Atezolizumab/ bevacizumab (Atz/Bev) has been widely used in patients with advanced hepatocellular carcinoma (HCC)
Many practitioners start newer patients on the 600mg dose, then move to 1200mg for those wanting a stronger effect or continuing an existing treatment plan
Studies have shown MASLD alterations like hepatic triglyceride elevated levels, upregulation of genes related to lipid uptake and lipogenesis in germ free mice upon fecal matter transplant (FMT) from hepatic steatosis suffering obese mice (91)
Isnt it dangerous to measure by volume using a teaspoon instead of weighing the ascorbic acid properly
Establishment of continuous multi-stage countercurrent water extraction process of tea saponin from camellia meal